Achieve Life Sciences, Inc. (ACHV)

Price$5.13

Value ScoreF

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-2.09%

Price vs S&P 500 (4W)6.95%

VGM Score34.39

Market Capitalization$526.64M

All Metrics

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)12.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-44.67%

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)-4.58%

Net Profit Margin (TTM)-94.67%

EPS (TTM)$-1.11

10-Day Avg Trading Volume1.30M

EPS Excl Extra (TTM)$-1.11

Revenue Growth (5Y)-1.65%

EPS (Annual)$-1.25

ROI (Annual)-150.10%

Gross Margin (Annual)-98.76%

Net Profit Margin (5Y Avg)-159.73%

Cash / Share (Quarterly)$0.55

ROA (Last FY)-130.77%

Revenue Growth TTM (YoY)-89.25%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-222.50%

Operating Margin (TTM)-106.51%

Cash Flow / Share (Annual)$-0.93

P/B Ratio49.32x

P/B Ratio (Quarterly)14.66x

Net Income / Employee (Annual)$-1,951,700

EV / Revenue (TTM)28.81x

Net Interest Coverage (TTM)-88.50x

ROA (TTM)-111.88%

EPS Incl Extra (Annual)$-1.25

Current Ratio (Annual)4.39x

Quick Ratio (Quarterly)2.47x

3-Month Avg Trading Volume1.09M

52-Week Price Return38.12%

Revenue / Employee (TTM)$75,700

Tangible BV / Share (Quarterly)$0.19

P/S Ratio (Annual)104.08x

Asset Turnover (Annual)0.18x

52-Week High$6.15

Operating Margin (5Y Avg)-175.65%

EPS Excl Extra (Annual)$-1.25

CapEx CAGR (5Y)-31.57%

Tangible BV CAGR (5Y)5.41%

26-Week Price Return9.30%

Quick Ratio (Annual)4.01x

13-Week Price Return15.50%

Total Debt / Equity (Annual)0.69x

Current Ratio (Quarterly)2.62x

Enterprise Value$513.46M

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)-49.48%

Revenue / Employee (Annual)$180,700

Pretax Margin (Annual)-397.83%

Cash / Share (Annual)$0.68

3-Month Return Std Dev118.93%

Gross Margin (5Y Avg)-120.50%

Net Income / Employee (TTM)$-1,856,800

ROE (Last FY)-253.96%

Net Interest Coverage (Annual)-95.08x

EPS Basic Excl Extra (Annual)$-1.25

P/FCF (TTM)87.05x

Receivables Turnover (TTM)20.24x

Total Debt / Equity (Quarterly)1.40x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)20.65x

ROI (TTM)-132.45%

P/S Ratio (TTM)29.55x

Pretax Margin (5Y Avg)-159.73%

Revenue / Share (Annual)$506.00

Tangible BV / Share (Annual)$0.39

Price vs S&P 500 (52W)11.08%

Year-to-Date Return6.44%

5-Day Price Return0.95%

EPS Normalized (Annual)$-1.25

ROA (5Y Avg)-119.77%

Net Profit Margin (Annual)-397.83%

Month-to-Date Return0.95%

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-418.77%

LT Debt / Equity (Annual)0.52x

ROI (5Y Avg)-114.02%

LT Debt / Equity (Quarterly)0.87x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)15.68x

P/B Ratio (Annual)12.30x

Pretax Margin (TTM)-94.67%

Book Value / Share (Annual)$0.40

Price vs S&P 500 (13W)5.00%

Beta2.32x

P/FCF (Annual)15.11x

Revenue / Share (TTM)$212.00

ROE (TTM)-193.49%

52-Week Low$2.00

vGradeF

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.19est. -0.31

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.08

4.07

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACHVAchieve Life Sciences, Inc.	F	F	B	$5.13
IDXXIdexx Laboratories Inc	D	B	C	$562.16
LNTHLantheus Holdings, Inc	C	B	B	$100.98
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	B	$22.99
CLDXCelldex Therapeutics, Inc	F	F	C	$28.62
NEOGNeogen Corp	C	C	B	$8.90
NTLAIntellia Therapeutics, Inc	D	C	B	$13.54
QDELQuidelOrtho Corporation Common Stock	C	C	D	$14.33
MYGNMyriad Genetics Inc	C	C	C	$4.57
TKNOAlpha Teknova, Inc. Common Stock	C	C	B	$4.56
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$5.24

About

Achieve Life Sciences is a specialty pharmaceutical company developing and commercializing cytisinicline, an established smoking cessation treatment approved in Central and Eastern Europe. The company aims to expand cytisinicline's availability as a treatment for nicotine addiction and address the global smoking health epidemic.